Malignancy and rheumatoid arthritis

被引:32
作者
Askling J. [1 ]
机构
[1] Clinical Epidemiology Unit M9:01, Department of Medicine Solna, Karolinska University Hospital Solna
关键词
Rheumatoid Arthritis; Cancer Risk; Abatacept; Cancer Occurrence; Rheumatoid Arthritis Treatment;
D O I
10.1007/s11926-007-0067-1
中图分类号
学科分类号
摘要
The occurrence of cancer is not an infrequent event in patients with rheumatoid arthritis (RA). Indeed, following diagnosis of RA at a typical age (55 years), one in five patients will be diagnosed with cancer. In the vast majority of such cases, the cancer has nothing to do with RA or its treatment; rather, it represents the "background" risk applicable to all humans. In some cases, the cancer occurs as a result of factors also associated with the risk of developing RA (eg, smoking), even though no direct link exists between the cancer and the RA. In a fraction of cases, however, the cancer is causally associated with the RA disease or its treatments. This review summarizes our current understanding of the occurrence of cancer in RA, possible links to RA disease and to traditional and newer RA treatments. Copyright © 2007 by Current Medicine Group LLC.
引用
收藏
页码:421 / 426
页数:5
相关论文
共 50 条
  • [31] Rheumatoid arthritis and cancer risk
    Mellemkjaer, L
    Linet, MS
    Gridley, G
    Frisch, M
    Moller, H
    Olsen, JH
    EUROPEAN JOURNAL OF CANCER, 1996, 32A (10) : 1753 - 1757
  • [32] Abatacept treatment for rheumatoid arthritis
    Schiff, Michael
    RHEUMATOLOGY, 2011, 50 (03) : 437 - 449
  • [33] Abatacept for the treatment of rheumatoid arthritis
    Pombo-Suarez, Manuel
    Gomez-Reino, Juan J.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2019, 15 (04) : 319 - 326
  • [34] Biological therapies in rheumatoid arthritis
    Garcia, Corte J. J.
    Prada Lobato, J.
    Lopez Garrido, S.
    Espin Fernandez, M.
    Royo Eyaralar, J.
    ATENCION FARMACEUTICA, 2008, 10 (02): : 98 - +
  • [35] Targeted therapy in rheumatoid arthritis
    Koeller, Marcus D.
    EXPERT OPINION ON DRUG DISCOVERY, 2008, 3 (03) : 329 - 342
  • [36] Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: A multi-database cohort study
    Kim, Seoyoung C.
    Pawar, Ajinkya
    Desai, Rishi J.
    Solomon, Daniel H.
    Gale, Sara
    Bao, Min
    Sarsour, Khaled
    Schneeweiss, Sebastian
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2019, 49 (02) : 222 - 228
  • [37] Emerging drugs for rheumatoid arthritis
    Voulgari, Paraskevi V.
    EXPERT OPINION ON EMERGING DRUGS, 2008, 13 (01) : 175 - 196
  • [38] The Burden of Disease in Rheumatoid Arthritis
    Till Uhlig
    Rikke H. Moe
    Tore K. Kvien
    PharmacoEconomics, 2014, 32 : 841 - 851
  • [39] Updates in the Treatment of Rheumatoid Arthritis
    Fantus, Sarah A.
    Ruderman, Eric M.
    CURRENT TREATMENT OPTIONS IN RHEUMATOLOGY, 2021, 7 (02) : 99 - 111
  • [40] Abatacept in the treatment of rheumatoid arthritis
    Posadas, Augusto
    Lisse, Jeffrey
    Sarkar, Sujata
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2009, 5 (01) : 9 - 17